Pdb10 Incidence, Management and Cost of Cardio-Vascular and Renal Complications in French Type 2 Diabetic Patients

Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective

“…Coronary complication costs for France were obtained from published literature (20–23) and inflated to 2004 values according to INSEE data (Table 3). Costs for treatment of angina and MI were subdivided into the cost of care during the first year postevent (including the cost of acute care) and the cost of longer‐term follow‐up care.…”

Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance®) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting

“…Direct costs were calculated as the sum of costs relating to treatment, complications and medication in France, according to published sources updated to 2005 as necessary. [11][12][13][14][15][16][17][18][19][20][21][22] All costs were reported in Euros and the cost-effectiveness analysis was performed from a third-party healthcare payer perspective. Acquisition costs for 2005 23 of Glucovance ® , glibenclamide and metformin were based on average within-trial dosages to most accurately reflect the trial conditions in a large study population: these were 1,660 mg for metformin 500 mg (annual cost €107), 13.4 mg for glibenclamide 5 mg (annual cost €120), 1,225/6.1 mg for Glucovance ® 500 mg/2.5 mg (annual cost €155) and 1,170/11.7 mg for Glucovance ® 500 mg/5 mg (annual cost €142).…”